| Nephrocare Health Services Limited, formerly Nephrocare Health Services Private Limited, reported consolidated revenue from operations of Rs 2,817.54 crore for the quarter ended June 30, 2026, a rise from Rs 2,277.83 crore in the comparable quarter of 2025. Revenue was generated from India (Rs 1,553.79 crore), the Philippines (Rs 906.29 crore), Uzbekistan (Rs 321.34 crore), and other regions (Rs 36.12 crore). The company, listed on the NSE and BSE since December 17, 2025, has utilized Rs 2,074.83 crore of its net IPO proceeds for capital expenditure and general corporate purposes, with Rs 1,176.70 crore remaining unutilized. Nephrocare has also entered into asset transfer arrangements totaling Rs 709.30 crore, with provisional accounting currently in place, and incorporated a new subsidiary in Kazakhstan. The Chairman and Managing Director oversees financial performance, and results are available on the company's and exchange websites. |